A9 and A10 aptamers are PSMA aptamers screened by Lupold et al. Farokhzad et al. published the first report of targeted drug delivery with nanoparticle-aptamer bioconjugates.243 They used PSMA’s RNA aptamer A10 and polymer nanoparticles to form bioconjugates, and proved that these bioconjugates can effectively target prostate cancer epithelial cells and be more absorbed. Here, FOLH1 is linked to prostate carcinoma.